ClinicalTrials.gg
RecruitingNCT07697443Updated Oct 20, 2026

Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects

A Phase 1/2 interventional study of TQB3126 in Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 20, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited — 11 open to participants now, 16 under way, 8 of them phase 3. Breast Neoplasms · Sino Biopharmaceutical Limited.

Planned enrollment
9th of 28
300 · median 138
Started
2026
with 1 other
Phase 1/2
5 of 28
2 open now
Primary completion
2029-08
later than 15 of 15 live
Registered
28th of 28
by date

Among the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, this one is the 9th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 15 of the 15 other live ones, and was the 28th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

The study includes Phase I dose escalation and expansion and Phase II combination therapy. It uses a multicenter, open-label, non-randomized design to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3126 in breast cancer. Phase I dose escalation uses a Rolling 6 design after accelerated titration at the first dose, with dose decisions reviewed by the Safety Review Committee. Dose expansion includes two cohorts of approximately 20-60 participants each. The study also explores relationships between drug exposure and efficacy/safety, including concentration-QTc assessment using Holter electrocardiograms.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily participate in this study, sign the form, and demonstrate good treatment compliance.
  2. Aged 18 to 75 years at the time of informed consent signature; (ECOG) performance status (PS) score of 0 or 1; estimated survival expectancy of more than 3 months.
  3. Histopathologically confirmed breast cancer.
  4. Documented disease progression confirmed by clinical or imaging evidence during or after the most recent prior systemic therapy prior to the first study drug administration.
  5. Have evaluable lesions per v1.1 criteria (; or bone-only with at least one osteolytic or mixed lesion).
  6. Adequate tissue samples shall be provided at screening for gene mutation testing to clarify genetic status.
  7. Laboratory test results meet the criteria specified in the protocol (blood routine, liver and renal function, coagulation function, cardiac ultrasound (LVEF) and other indicators are all within the protocol-specified ranges).
  8. Subjects of must agree to use effective measures throughout the study and for 6 months after study completion (the same requirement applies to male subjects); serum or urine pregnancy test result is negative within 7 days prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Other malignant tumors within 5 years prior to first dose, except those cured by single surgical treatment with at least 5 years of disease-free survival, or cured differentiated thyroid cancer, cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder tumors.
  2. Conditions affecting intravenous access or blood sampling, or multiple factors affecting oral drug administration/absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction).
  3. Unresolved toxicity from prior therapy of Grade >1 ( v6.0), except Grade 2 alopecia, Grade 2 anemia, clinically insignificant laboratory abnormalities, or hypothyroidism stable on hormone replacement therapy.
  4. Major surgery, significant traumatic injury within 4 weeks before first dose, anticipated need for major surgery during the study, or long-standing unhealed fracture.
  5. Any bleeding event of Grade >=3 within 4 weeks before first dose.
  6. Arterial/venous thrombotic events within 6 months before first dose (e.g., cerebrovascular accident, deep vein thrombosis, pulmonary embolism), excluding catheter-related or superficial venous thrombosis.
  7. Active viral hepatitis that is poorly controlled ( Virus (HBV)/ Virus (HCV)-infected subjects meeting protocol-specified criteria may be enrolled).
  8. Active syphilis infection requiring treatment.
  9. Active tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced or radiation pneumonitis requiring treatment, or history of/current interstitial lung disease (ILD).
  10. History of psychotropic substance abuse unable to be discontinued, mental disorders, epilepsy requiring treatment, or severe psychiatric/neurological disease.
  11. Planned or prior allogeneic bone marrow or solid organ transplantation.
  12. Decompensated cirrhosis ( Class B or C) or history of hepatic encephalopathy.
  13. Significant cardiovascular disease, including (NYHA) Class >II heart failure, ventricular arrhythmia, unstable angina, myocardial infarction within 12 months, markedly prolonged corrected by Fridericia's formula (QTcF), or personal/family history of congenital long QT syndrome.
  14. Poorly controlled hypertension (resting systolic BP >=160 mmHg or diastolic BP >=100 mmHg on at least 2 measurements >=24 hours apart).
  15. Active or uncontrolled serious infection (Grade >=2).
  16. Renal failure requiring hemodialysis or peritoneal dialysis; or history of/current nephrotic syndrome (except cured) or chronic nephritis.
  17. History of immunodeficiency, including infection or other acquired/congenital immunodeficiency diseases.
  18. Poorly controlled disease requiring or systemic for immunosuppression, continued within 7 days before first dose (except low-dose corticosteroids).
  19. Clinically significant endometrial abnormalities (including hyperplasia, dysfunctional uterine bleeding, etc.).
  20. Tumor-related conditions/treatments: anti-cancer therapy within 3 weeks before first dose or still within the drug's ; prior local radiotherapy not meeting protocol-specified interval or target lesion requirements; use of National Medical Products Administration (NMPA)-approved proprietary Chinese medicine with anti-tumor indications within 1 week before first dose; imaging showing tumor invasion of major vessels with risk of fatal hemorrhage; uncontrolled pleural effusion/ascites/moderate-or-greater pericardial effusion requiring repeated drainage; known or uncontrolled symptoms; severe skeletal-related events due to bone .
  21. Known to the study drug or its .
  22. Participation in and use of another anti-tumor drug within 4 weeks before first dose.
  23. Any concomitant disease or condition that, in the investigator's judgment, seriously endangers subject safety or study compliance, or any other reason making the subject unsuitable for enrollment.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    TQB3126

    TQB3126 is to be administered orally in accordance with the protocol. Dose modifications and adjustments to the dosing frequency shall be made only with the unanimous consent of the SRC.

    Drug: TQB3126

Interventions

  • DrugTQB3126

    TQB3126 is a targeted protein degrader.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    DLT is defined as toxicities that meet pre-defined severity criteria (according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 6.0) and are assessed as related to TQB3126, occurring from the first dose to the end of the first treatment cycle.

    Time frame: From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.

  2. Maximum Tolerated Dose (MTD)

    MTD is the highest dose at which DLT occurs in less than 33% of evaluable subjects during the DLT assessment window, from the first dose of TQB3126 through the end of the first repeated-dose treatment cycle.

    Time frame: From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.

  3. Recommended Phase II Dose (RP2D)

    The dose recommended for Phase II study based on integrated safety, tolerability, pharmacokinetic and efficacy data.

    Time frame: Observation is expected to continue through Cycle 6 Day 28 throughout the study, around 6 months.

  4. Adverse Events (AEs)

    The occurrence, incidence and severity of all adverse events (AEs).

    Time frame: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.

  5. Serious Adverse Events (SAEs)

    The occurrence, incidence and severity of all serious adverse events (SAEs).

    Time frame: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.

  6. Abnormal Incidence of Laboratory Test Indicators

    Incidence and severity of abnormal laboratory values.

    Time frame: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.

  7. Objective Response Rate (ORR)

    The proportion of subjects with a best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1.

    Time frame: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.

  8. Maximum Applicable Dose (MAD)

    MAD is the dose at which a dose-exposure plateau is reached, further dose escalation poses substantial safety risk, or available data indicate that a safe and effective optimal target dose has been identified.

    Time frame: From the first dose of TQB3126 through completion of the Phase I dose-escalation assessment.

Secondary outcomes

  1. Peak Concentration (Cmax)

    Maximum observed plasma concentration of TQB3126.

    Time frame: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.

  2. Time to Reach Maximum Plasma Concentration (Tmax)

    Time to reach the maximum plasma concentration of TQB3126.

    Time frame: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.

  3. Elimination Half-life (t1/2)

    Elimination half-life of TQB3126 after oral dosing.

    Time frame: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.

  4. Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t)

    Area under the plasma concentration-time curve from time zero to the last measurable concentration.

    Time frame: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.

  5. Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞)

    Area under the plasma concentration-time curve from time zero extrapolated to infinity.

    Time frame: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.

  6. Apparent Clearance (CL/F)

    Apparent total clearance of TQB3126 from plasma.

    Time frame: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.

  7. Apparent Volume of Distribution (Vz/F)

    Apparent volume of distribution of TQB3126 in plasma.

    Time frame: Escalation: pre-dose+0.5,1,2,3,4,6,8,12,24,48,72,120 hours post single dose (Cycle0); pre-dose Cycle1 Day1. Expansion/combo: pre-dose+0.5-12 hours Cycle1 Day1; 24 hours Day2. All: pre-dose Day 7,14,21; pre-dose+0.5-12 hours Day 28; pre-dose Cycle2 Day1.

  8. Clinical Benefit Rate (CBR)

    The proportion of subjects with a best overall response of complete response, partial response, or stable disease lasting a pre-specified minimum duration, per RECIST v1.1.

    Time frame: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.

  9. Disease Control Rate (DCR)

    The proportion of subjects with a best overall response of complete response, partial response, or stable disease, per RECIST v1.1.

    Time frame: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.

  10. Duration of Response (DOR)

    The time from the first documentation of complete or partial response to the first documentation of disease progression.

    Time frame: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.

  11. Progression-Free Survival (PFS)

    The time from the first dose to the first documentation of disease progression or death from any cause, whichever occurs first.

    Time frame: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.

  12. Time to Response (TTR)

    The time from the first dose to the first documentation of complete or partial response.

    Time frame: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.

Other outcomes

  1. Relationship Between TQB3126 Exposure and Efficacy/Safety

    Explore relationships between the pharmacokinetics of TQB3126 monotherapy or combination therapy and efficacy/safety in Phase I and Phase II. Holter electrocardiogram data are collected to support exploratory concentration-QTc (C-QTc) analyses. Holter is performed on Cycle 0 Day 1 and Cycle 1 Day 28 in dose escalation, and on Cycle 1 Day 1 and Cycle 1 Day 28 in dose expansion and combination-therapy participants undergoing PK sampling. Monitoring starts within 1 hour before dosing and continues through 24 hours after dosing; on Cycle 1 Day 28, it continues at least until 30 minutes before the predose blood collection on Cycle 2 Day 1.

    Time frame: PK/Holter: Cycle 0 (7-day washout), Cycles 1-2 (28 days each); efficacy: until disease progression; safety: first dose to 28 days after last dose or start of other anticancer therapy, whichever occurs first.

07

Study locations

6 of 6 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2029, 35 months after the start.

Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 35 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartActual
Sep 12, 2026was Aug 2026
Primary completionEst.
Aug 2029
CompletionEst.
Aug 2030
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 20, 2026
Sites
6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangzhou, Chinano status→Recruiting
  • Meizhou People's Hospital · Meizhou, Chinano status→Recruiting
  • Zhongnan Hospital of Wuhan University · Wuhan, Chinano status→Recruiting
  • The Third Xiangya Hospital of Central South University · Changsha, Chinano status→Recruiting
  • Sichuan Cancer Hospital · Chengdu, Chinano status→Recruiting
  • Tianjin Medical University Cancer Institute & Hospital · Tianjin, Chinano status→Recruiting
Oct 20, 2026
Start date
Aug 2026→Sep 12, 2026 (actual)
Oct 20, 2026
Enrollment
306→300
Oct 20, 2026
Primary outcomes
1 added, 1 description edited
What changed in the outcomes
  • AddedMaximum Applicable Dose (MAD)Time frame: From the first dose of TQB3126 through completion of the Phase I dose-escalation assessment.
  • DescriptionMaximum Tolerated Dose (MTD): how it is measured was reworded
Oct 20, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • Addedother outcomeRelationship Between TQB3126 Exposure and Efficacy/SafetyTime frame: PK/Holter: Cycle 0 (7-day washout), Cycles 1-2 (28 days each); efficacy: until disease progression; safety: first dose to 28 days after last dose or start of other anticancer therapy, whichever occurs first.
Oct 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The Third Xiangya Hospital of Central South University · Changsha, ChinaContact added g•••@163.com · •••2599
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Recruiting
    6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangzhou, Chinano status→Recruiting
    • Meizhou People's Hospital · Meizhou, Chinano status→Recruiting
    • Zhongnan Hospital of Wuhan University · Wuhan, Chinano status→Recruiting
    • The Third Xiangya Hospital of Central South University · Changsha, Chinano status→Recruiting
    • Sichuan Cancer Hospital · Chengdu, Chinano status→Recruiting
    • Tianjin Medical University Cancer Institute & Hospital · Tianjin, Chinano status→Recruiting
    Start date Aug 2026→Sep 12, 2026 (now actual)
    Enrollment 306→300
    Primary outcomes 1 added, 1 description edited
    What changed in the outcomes
    • AddedMaximum Applicable Dose (MAD)Time frame: From the first dose of TQB3126 through completion of the Phase I dose-escalation assessment.
    • DescriptionMaximum Tolerated Dose (MTD): how it is measured was reworded
    Secondary outcomes 1 added
    What changed in the outcomes
    • Addedother outcomeRelationship Between TQB3126 Exposure and Efficacy/SafetyTime frame: PK/Holter: Cycle 0 (7-day washout), Cycles 1-2 (28 days each); efficacy: until disease progression; safety: first dose to 28 days after last dose or start of other anticancer therapy, whichever occurs first.
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The Third Xiangya Hospital of Central South University · Changsha, ChinaContact added g•••@163.com · •••2599
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07697443
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Sep 12, 2026
Primary completion
Aug 2029 (estimated)
Completion
Aug 2030 (estimated)
Last update
Oct 20, 2026

Study contacts

Herui Yao, Doctor
Contact
yaohrsysu@163.com
+86 13500018020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion